|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the correlation between the polymorphism of estrogen receptor β gene (ESR2) rs3020450 and cancer susceptibility, and explore the epidemiological significance and the effect of ESR2 expression levels on the prognosis of ovarian cancer.
|
31200086 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings demonstrated that ERα, but not ERβ, is involved in leptin-induced ovarian cancer in an E2-independent manner, providing new evidence for cancer progression in obesity-associated ovarian cancer.
|
31077012 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, FRBI will possibly be utilized to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries.
|
29783074 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the effects of genistein, daidzein and ERB-041 on ovarian cancer.
|
29743815 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presented data suggest that selective targeting of ERβ with an agonist potentiate chemotherapy efficacy for the treatment of ovarian cancer and that downregulation or inhibition of SIRT1 may further enhance its therapeutic effect.
|
29422491 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.
|
29535531 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall survival of patients with tumors expressing cytoplasmic ERβ was significant longer compared to those with ERβ-negative ovarian cancer (chi-square statistic of the log-rank, p < 0.05).
|
30326857 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings demonstrated that natural ERβ agonists have the potential to significantly inhibit ovarian cancer cell growth by anti-inflammatory and pro-apoptotic actions, and natural ERβ agonists represent novel therapeutic agents for the management of ovarian cancer.
|
28654894 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the effects of four ERβ agonists on proliferation and gene expression of two ovarian cancer cell lines.
|
28482871 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical utilization of ERβ actions in the management of ovarian cancer is discussed in an up-to-date review.
|
26861465 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that SNPs in the promoter region of ESR2 gene do not affect susceptibility to ovarian cancer, but SNP rs3020449 might affect progression of this disease.
|
24881814 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of ERβ isoforms in a panel of ovarian cancer cell lines and human tumor xenografts was also assessed.
|
24378878 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate that PES1 may play important role in the progression of ovarian cancer by inversely regulating the ERα and ERβ expression.
|
24376209 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer.
|
22970307 |
2012 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERβ may also exhibit antitumorigenic properties, with a decline in ERβ levels in epithelial ovarian cancers associated with more severe disease and poor prognosis.
|
22271292 |
2012 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.
|
21673961 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined the mRNA expression of HYAL1, estrogen receptor (ER)-α, ERβ and progesterone receptor (PR) in EOC tumor samples and cell lines using quantitative RT-PCR.
|
21695196 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells.
|
19331143 |
2009 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that ESR2 might be a susceptibility marker for epithelial ovarian cancer.
|
18704709 |
2009 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using the genetic structure data generated by the Breast and Prostate Cohort Consortium (BPC3), we have comprehensively characterized the role of haplotype diversity in ESR2 and risk of ovarian cancer.
|
18268123 |
2008 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
|
19032364 |
2008 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The loss of ERbeta expression may thus be an important event leading to the development of ovarian cancer.
|
15313930 |
2004 |